vs
AtriCure, Inc.（ATRC）与CSW INDUSTRIALS, INC.（CSW）财务数据对比。点击上方公司名可切换其他公司
CSW INDUSTRIALS, INC.的季度营收约是AtriCure, Inc.的1.6倍（$233.0M vs $141.2M），CSW INDUSTRIALS, INC.净利率更高（4.4% vs 0.1%，领先4.3%），CSW INDUSTRIALS, INC.同比增速更快（20.3% vs 14.3%），过去两年AtriCure, Inc.的营收复合增速更高（10.2% vs 5.1%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
ATRC vs CSW — 直观对比
营收规模更大
CSW
是对方的1.6倍
$141.2M
营收增速更快
CSW
高出6.1%
14.3%
净利率更高
CSW
高出4.3%
0.1%
两年增速更快
ATRC
近两年复合增速
5.1%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $141.2M | $233.0M |
| 净利润 | $108.0K | $10.3M |
| 毛利率 | 77.4% | 39.7% |
| 营业利润率 | 23.0% | 7.4% |
| 净利率 | 0.1% | 4.4% |
| 营收同比 | 14.3% | 20.3% |
| 净利润同比 | — | -61.9% |
| 每股收益（稀释后） | $0.00 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCCSW
| Q1 26 | $141.2M | — | ||
| Q4 25 | $140.5M | $233.0M | ||
| Q3 25 | $134.3M | $277.0M | ||
| Q2 25 | $136.1M | $263.6M | ||
| Q1 25 | $123.6M | $230.5M | ||
| Q4 24 | $124.3M | $193.6M | ||
| Q3 24 | $115.9M | $227.9M | ||
| Q2 24 | $116.3M | $226.2M |
净利润ATRCCSW
| Q1 26 | $108.0K | — | ||
| Q4 25 | — | $10.3M | ||
| Q3 25 | $-267.0K | $40.7M | ||
| Q2 25 | $-6.2M | $40.9M | ||
| Q1 25 | $-6.7M | $35.1M | ||
| Q4 24 | — | $26.9M | ||
| Q3 24 | $-7.9M | $36.1M | ||
| Q2 24 | $-8.0M | $38.6M |
毛利率ATRCCSW
| Q1 26 | 77.4% | — | ||
| Q4 25 | 75.0% | 39.7% | ||
| Q3 25 | 75.5% | 43.0% | ||
| Q2 25 | 74.5% | 43.8% | ||
| Q1 25 | 74.9% | 44.2% | ||
| Q4 24 | 74.5% | 41.4% | ||
| Q3 24 | 74.9% | 45.6% | ||
| Q2 24 | 74.7% | 47.5% |
营业利润率ATRCCSW
| Q1 26 | 23.0% | — | ||
| Q4 25 | 1.8% | 7.4% | ||
| Q3 25 | 0.2% | 20.5% | ||
| Q2 25 | -4.5% | 20.8% | ||
| Q1 25 | -4.8% | 19.5% | ||
| Q4 24 | -11.7% | 15.3% | ||
| Q3 24 | -6.4% | 22.6% | ||
| Q2 24 | -6.2% | 24.3% |
净利率ATRCCSW
| Q1 26 | 0.1% | — | ||
| Q4 25 | — | 4.4% | ||
| Q3 25 | -0.2% | 14.7% | ||
| Q2 25 | -4.5% | 15.5% | ||
| Q1 25 | -5.5% | 15.2% | ||
| Q4 24 | — | 13.9% | ||
| Q3 24 | -6.8% | 15.8% | ||
| Q2 24 | -6.9% | 17.1% |
每股收益（稀释后）ATRCCSW
| Q1 26 | $0.00 | — | ||
| Q4 25 | $0.04 | $0.62 | ||
| Q3 25 | $-0.01 | $2.41 | ||
| Q2 25 | $-0.13 | $2.43 | ||
| Q1 25 | $-0.14 | $2.05 | ||
| Q4 24 | $-0.33 | $1.60 | ||
| Q3 24 | $-0.17 | $2.26 | ||
| Q2 24 | $-0.17 | $2.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.2M | $40.2M |
| 总债务越低越好 | $61.0M | — |
| 股东权益账面价值 | $491.7M | $1.1B |
| 总资产 | $644.0M | $2.3B |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资ATRCCSW
| Q1 26 | $146.2M | — | ||
| Q4 25 | $167.4M | $40.2M | ||
| Q3 25 | $147.9M | $31.5M | ||
| Q2 25 | $117.8M | $38.0M | ||
| Q1 25 | $99.9M | $225.8M | ||
| Q4 24 | $122.7M | $213.8M | ||
| Q3 24 | $130.3M | $273.2M | ||
| Q2 24 | $114.0M | $18.9M |
总债务ATRCCSW
| Q1 26 | $61.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $61.9M | — | ||
| Q2 25 | $61.9M | — | ||
| Q1 25 | $61.9M | $800.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | $61.9M | — | ||
| Q2 24 | $61.9M | — |
股东权益ATRCCSW
| Q1 26 | $491.7M | — | ||
| Q4 25 | $491.9M | $1.1B | ||
| Q3 25 | $476.5M | $1.1B | ||
| Q2 25 | $464.5M | $1.1B | ||
| Q1 25 | $454.6M | $1.1B | ||
| Q4 24 | $461.0M | $1.0B | ||
| Q3 24 | $465.0M | $1.0B | ||
| Q2 24 | $462.1M | $650.2M |
总资产ATRCCSW
| Q1 26 | $644.0M | — | ||
| Q4 25 | $654.2M | $2.3B | ||
| Q3 25 | $635.4M | $1.5B | ||
| Q2 25 | $608.8M | $1.5B | ||
| Q1 25 | $591.6M | $1.4B | ||
| Q4 24 | $609.3M | $1.4B | ||
| Q3 24 | $615.1M | $1.4B | ||
| Q2 24 | $597.3M | $1.1B |
负债/权益比ATRCCSW
| Q1 26 | 0.12× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | — | ||
| Q1 25 | 0.14× | 0.75× | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $28.9M |
| 自由现金流经营现金流 - 资本支出 | — | $22.7M |
| 自由现金流率自由现金流/营收 | — | 9.8% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 2.81× |
| 过去12个月自由现金流最近4个季度 | — | $162.0M |
8季度趋势，按日历期对齐
经营现金流ATRCCSW
| Q1 26 | — | — | ||
| Q4 25 | $20.0M | $28.9M | ||
| Q3 25 | $26.7M | $61.8M | ||
| Q2 25 | $21.6M | $60.6M | ||
| Q1 25 | $-11.0M | $27.3M | ||
| Q4 24 | $5.8M | $11.6M | ||
| Q3 24 | $20.0M | $66.8M | ||
| Q2 24 | $7.4M | $62.7M |
自由现金流ATRCCSW
| Q1 26 | — | — | ||
| Q4 25 | $18.4M | $22.7M | ||
| Q3 25 | $24.1M | $58.7M | ||
| Q2 25 | $19.0M | $57.7M | ||
| Q1 25 | $-13.2M | $22.8M | ||
| Q4 24 | $3.1M | $8.5M | ||
| Q3 24 | $16.4M | $61.3M | ||
| Q2 24 | $5.0M | $59.6M |
自由现金流率ATRCCSW
| Q1 26 | — | — | ||
| Q4 25 | 13.1% | 9.8% | ||
| Q3 25 | 18.0% | 21.2% | ||
| Q2 25 | 13.9% | 21.9% | ||
| Q1 25 | -10.7% | 9.9% | ||
| Q4 24 | 2.5% | 4.4% | ||
| Q3 24 | 14.1% | 26.9% | ||
| Q2 24 | 4.3% | 26.3% |
资本支出强度ATRCCSW
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 2.6% | ||
| Q3 25 | 1.9% | 1.1% | ||
| Q2 25 | 2.0% | 1.1% | ||
| Q1 25 | 1.8% | 2.0% | ||
| Q4 24 | 2.2% | 1.6% | ||
| Q3 24 | 3.1% | 2.4% | ||
| Q2 24 | 2.1% | 1.4% |
现金转化率ATRCCSW
| Q1 26 | — | — | ||
| Q4 25 | — | 2.81× | ||
| Q3 25 | — | 1.52× | ||
| Q2 25 | — | 1.48× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 1.85× | ||
| Q2 24 | — | 1.62× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage management | $48.4M | 34% |
| Open ablation | $39.1M | 28% |
| Other | $25.0M | 18% |
| Pain management | $22.4M | 16% |
| Minimally invasive ablation | $6.4M | 5% |
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
